Rubicon Research
Rubicon Research Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #18 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Rubicon Research Q1 FY27 key numbers
- Revenue
- USD revenue for Q1 was $55 million, up 32% year-on-year, despite a slight sequential drop due to tactical measures.
As stated in Rubicon Research's Q1 FY27 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.
The short version
Revenue growth remains strong and broad-based, driven by a specialty and differentiated product portfolio. Rubicon Research demonstrated strong Q1 FY27 performance with 51% YoY revenue growth, 65% EBITDA growth, and 95% PAT growth, indicating robust earnings momentum.
From Rubicon Research's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Revenue growth remains strong and broad-based, driven by a specialty and differentiated product portfolio.
- USD revenue for Q1 was $55 million, up 32% year-on-year, despite a slight sequential drop due to tactical measures.
- Expect strong revenue traction in coming quarters with a continued focus on higher margin specialty products.
- Product commercialization rate remains strong at 88%, supporting sustained revenue growth.
- New facility ramp-up at Pithampur expected to start commercialization in calendar year 2027 with significant capacity expansion headroom available for medium to long term growth.
- Pipeline and approvals are on track as per plan, supporting future revenue expansion.
2 more points from Rubicon Research's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rubicon Research said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Pithampur facility has around INR 1,500 million capital sitting pre-revenue with commercialization and ramp-up expected from Q1; capacity utilization is planned to scale up gradually over the next 6-12 months.
- The Pithampur site spans nearly 30 acres, with only 5-6 acres currently utilized, leaving significant headroom for quick capacity expansion over the next 2-3 years.
- Manufacturing infrastructure investments are strategically aligned with product portfolio needs and involve capacity expansion as revenue visibility increases.
- The company follows a portfolio-based CMO/manufacturing strategy balancing risk diversification and capacity building.
2 more points from Rubicon Research's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rubicon Research said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company shared that they provide updates on specialty portfolio gross profit and number of specialty products once a year.
- Management emphasized consistent revenue growth and strong visibility for revenue in coming quarters.
- The ramp-up of the Pithampur manufacturing facility is planned for the next 6-12 months, indicating expected volume increase tied to orders.
- The focus remains on securing higher margin business and selectively letting go of lower margin contracts, implying a qualitative improvement in order book quality.
What the Q1 FY27 call signalled
2 of 3 strong
Rubicon Research — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹476 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rubicon Research Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rubicon Research and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rubicon Research Q1 FY27 results?
Revenue growth remains strong and broad-based, driven by a specialty and differentiated product portfolio. Rubicon Research demonstrated strong Q1 FY27 performance with 51% YoY revenue growth, 65% EBITDA growth, and 95% PAT growth, indicating robust earnings momentum.
What is Rubicon Research share price analysis?
Rubicon Research currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 99.0 with a market cap of ₹28,549 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research planning capital expenditure?
The Pithampur facility has around INR 1,500 million capital sitting pre-revenue with commercialization and ramp-up expected from Q1; capacity utilization is planned to scale up gradually over the next 6-12 months.
Keep Rubicon Research on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.